Background Angiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as
an innovative therapy for patients of heart failure with reduced ejection fraction (HFrEF). The …

Background: Iron deficiency (ID) is a common comorbidity among patients with heart failure
and reduced ejection fraction (HFrEF), and is associated with poorer outcomes independent …

Background: Vericiguat was developed to treat patients with heart failure (HF). Currently,
limited data are available to characterize vericiguat-treated patients in real-world clinical …

Background In the real-world setting, data regarding renal decline following
sacubitril/valsartan treatment are lacking. This study aimed to develop a scoring system to …

Background Heart failure (HF) is a significant public health problem worldwide. Death and
rehospitalization rates are similar across different HF phenotypes. However, the existing …

Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little
is known about its uses or impact in real-world practice in the Indian population. We …